# A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer

> **NCT00710762** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 89 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** BIBF1120
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00710762
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2008-09
- **Final completion:** 2014-03
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2016-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00710762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00710762, "A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00710762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*